Medicus Pharma (MDCX) Non Operating Income (2024 - 2025)
Medicus Pharma (MDCX) reported Non Operating Income of -$393957.0 for Q4 2025, down 905.69% on a YoY basis from $48897.0 in Q4 2024, and up 29.01% quarter-over-quarter from -$554972.0 in Q3 2025.
Medicus Pharma (MDCX) Non Operating Income (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Non Operating Income for 2 years, with the latest figure at -$393957.0 in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 905.69% year-over-year to -$393957.0; the trailing twelve-month figure through Dec 2025 stood at -$1.1 million (down 4374.24% YoY), and the FY2025 full-year result was -$1.1 million, down 4374.24% from the prior year.
- Non Operating Income for Q4 2025 stood at -$393957.0, up from -$554972.0 in the prior quarter.
- The five-year high for Non Operating Income was $55514.0 in Q3 2024, with the low at -$554972.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Medicus Pharma | 6.05 Mn | 6.15 Mn | - | -393,957.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -393,957.00 |
| Sep 30, 2025 | -554,972.00 |
| Jun 30, 2025 | -159,996.00 |
| Mar 31, 2025 | 23,866.00 |
| Dec 31, 2024 | 48,897.00 |
| Sep 30, 2024 | 55,514.00 |
| Jun 30, 2024 | -79,025.00 |